Black Diamond Therapeutics (BDTX) Price & Analysis

Compare

1,510 Followers

BDTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.20 - $6.43

Previous CloseN/A

Volume170.82K

Average Volume (3M)941.94K

Market Cap

$165.11M

Enterprise Value$18.80M

Total Cash (Recent Filing)$29.99M

Total Debt (Recent Filing)$16.97M

Price to Earnings (P/E)12.2

Beta2.23

Next Earnings

Nov 10, 2025

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding56,935,280

10 Day Avg. Volume976,178

30 Day Avg. Volume941,944

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.11

Enterprise Value/Revenue0.27

Enterprise Value/Gross Profit0.27

Enterprise Value/Ebitda3.79

Forecast

1Y Price Target

$10.50

Price Target Upside265.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Cash PositionBlack Diamond ended 2Q25 with approximately $143M in cash, cash equivalents, and marketable securities.

Clinical Trial ResultsInitial safety and efficacy results from the Ph. II trial of BDTX-1535 in NSCLC patients are considered encouraging and competitive with alternative non-targeted therapies.

Financial PerformanceBlack Diamond reported a net loss of $0.19 per share, which was better than the prior estimated net loss of $0.33 per share.

Bears Say

Competitive LandscapeThe evolving competitive landscape in 2L NSCLC presents challenges and a modest commercial opportunity.

Product Launch DelayThe initial U.S. launch of silevertinib (BDTX-1535) has been moved to 2028 from the prior 2026.

Black Diamond Therapeutics News

Black Diamond price target lowered to $10 from $12 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $10 from...

18d ago

BDTX

Black Diamond Therapeutics reports Q2 EPS (19c), consensus (23c)

“With enrollment completed in our silevertinib Phase 2 trial for the treatment of newly diagnosed patients with EGFRm...

22d ago

BDTX

Black Diamond Therapeutics sees cash runway into 4Q27

Black Diamond ended the second quarter of 2025 with approximately $142.8 million in cash, cash equivalents and investments,...

22d ago

BDTX

Black Diamond Therapeutics Reports Strong Financial Turnaround

Black Diamond Therapeutics, Inc. ( ($BDTX) ) has released its Q2 earnings. Here is a breakdown of the...

21d ago

BDTX

Black Diamond, Nike, Apple, Block, IonQ: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($BDTX) ), ( ($NKE) ), ( ($AAPL) ), ( ($XYZ)...

2M ago

NKE

XYZ

Optimistic Buy Rating for Black Diamond Therapeutics: Promising BDTX-1535 Drug and Strong Financial Position

Black Diamond Therapeutics (BDTX) has received a new Buy rating, initiated by Raymond James analyst, Sean McCutcheon. Sean...

2M ago

BDTX

Black Diamond Therapeutics resumed with an Outperform at Raymond James

Raymond James resumed coverage of Black Diamond Therapeutics (BDTX) with an Outperform rating and $11 price target BDTX-1535...

2M ago

BDTX

Black Diamond’s 2025 Annual Stockholders Meeting Highlights

An update from Black Diamond Therapeutics ( ($BDTX) ) is now available. On June 12, 2025, Black Diamond...

3M ago

BDTX

Black Diamond Therapeutics Reports Strong Q1 2025 Earnings

Black Diamond Therapeutics, Inc. ( ($BDTX) ) has released its Q1 earnings. Here is a breakdown of the...

3M ago

BDTX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

BMY

ABBV

Black Diamond Therapeutics reports Q1 diluted EPS 98c vs. (35c) last year

Black Diamond ended Q1 with approximately $152.4M in cash, cash equivalents, and investments compared to $98.6M as of...

4M ago

BDTX

3 Penny Stocks to Watch Now, 3/20/25

Black Diamond Therapeutics, Aterian, and Biodexa Pharmaceuticals are the 3 Penny Stocks to watch on March 20, 2025, based on TipRanks’...

5M ago

ATER

BDRX

Black Diamond Therapeutics Partners with Servier for BDTX-4933

An announcement from Black Diamond Therapeutics ( ($BDTX) ) is now available. On March 18, 2025, Black Diamond...

5M ago

BDTX

Black Diamond, Servier announce global licensing agreement for BDTX-4933

Servier and Black Diamond Therapeutics (BDTX) announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted...

5M ago

BDTX

BDTX FAQ

What was Black Diamond Therapeutics’s price range in the past 12 months?

Black Diamond Therapeutics lowest stock price was $1.20 and its highest was $6.43 in the past 12 months.

What is Black Diamond Therapeutics’s market cap?

Black Diamond Therapeutics’s market cap is $165.11M.

When is Black Diamond Therapeutics’s upcoming earnings report date?

Black Diamond Therapeutics’s upcoming earnings report date is Nov 10, 2025 which is in 73 days.

How were Black Diamond Therapeutics’s earnings last quarter?

Black Diamond Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.248 by $0.058.

Is Black Diamond Therapeutics overvalued?

According to Wall Street analysts Black Diamond Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Black Diamond Therapeutics pay dividends?

Black Diamond Therapeutics does not currently pay dividends.

What is Black Diamond Therapeutics’s EPS estimate?

Black Diamond Therapeutics’s EPS estimate is -0.23.

How many shares outstanding does Black Diamond Therapeutics have?

Black Diamond Therapeutics has 56,935,280 shares outstanding.

What happened to Black Diamond Therapeutics’s price movement after its last earnings report?

Black Diamond Therapeutics reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.248. Following the earnings report the stock price went down -15.242%.

Which hedge fund is a major shareholder of Black Diamond Therapeutics?

Currently, no hedge funds are holding shares in BDTX

Black Diamond Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

11.85%

Trailing 12-Months

Asset Growth

10.93%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Black Diamond Therapeutics

Black Diamond Therapeutics (BDTX) is a biotechnology company dedicated to the discovery and development of precision medicines for genetically defined cancers. The company focuses on creating innovative therapies that target oncogenic mutations, including previously undruggable mutations, using its proprietary Mutation-Allostery-Pharmacology (MAP) platform. Black Diamond Therapeutics is at the forefront of cancer treatment innovation, aiming to provide more effective and personalized treatment options for patients.

Black Diamond Therapeutics (BDTX) Earnings & Revenues

Historic Earnings Reports

BDTX Stock 12 Month Forecast

Average Price Target

$10.50

▲(265.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,3.236923076923077,3.8838461538461537,4.530769230769231,5.177692307692308,5.8246153846153845,6.4715384615384615,7.118461538461538,7.765384615384615,8.412307692307692,9.05923076923077,9.706153846153846,10.353076923076923,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,3.1984615384615385,3.806923076923077,4.415384615384616,5.023846153846154,5.632307692307693,6.240769230769231,6.849230769230769,7.457692307692308,8.066153846153846,8.674615384615386,9.283076923076923,9.891538461538461,{"y":10.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,3.16,3.73,4.3,4.87,5.44,6.01,6.58,7.15,7.720000000000001,8.290000000000001,8.86,9.43,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.93,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.78,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >